You are here: Industry Insights > FSHD

News List

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares firstwordpharma
August 17, 2021
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) today announced closing of its previously announced underwritten public offering of 7,590,000 shares of its common stock at a public offering price of $19.00 per share
Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial Use prnewswire
August 17, 2021
Avidity Biosciences, Inc. today announced its collaboration with the Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Trial Research Network (FSHD CTRN) to support a natural history study for people living with FSHD called the Motor Outcomes.
Fulcrum acquires global rights of investigational drug losmapimod from GSK pharmaceutical-business-review
April 24, 2019
Fulcrum Therapeutics has acquired all worldwide development and commercialization rights of investigational drug losmapimod from GlaxoSmithKline (GSK).